Search results
Results from the WOW.Com Content Network
St. Jude Medical was founded in 1976 to further develop bi-leaflet artificial heart valves, which were originally created in 1972 at the University of Minnesota. [4] [5] St. Jude Medical's bi-leaflet valve was developed in large part by Dr. Demetre Nicoloff of the University of Minnesota and St. Jude Medical employee Don Hanson.
The Medical Devices Division was spun off and went public in late 1994 under the name of Guidant Corporation (NYSE and PCX: GDT). The new company focused on cardiac rhythm management (pacemakers and implantable defibrillators) and cardiac and vascular intervention products via coronary and peripheral stents, guidewires and balloon dilatation ...
With the 2001 Thermo Cardiosystems merger, Thoratec acquired the HeartMate Left Ventricular Assist System, an implanted VAD for end-stage heart patients. A landmark three-year study of 129 patients at 22 major medical centers, called REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) and published in November 2001, found that the HeartMate VE ...
You wouldn't know that medical device makers Boston Scientific and St. Jude Medical are having a tough time by checking out their stock charts alone. Boston Scientific's hovering near a 52-week ...
St. Jude Medical (NYS: STJ) carries $3.9 billion of goodwill and other intangibles on its balance sheet. Sometimes goodwill, especially when it's excessive, can foreshadow problems down the road.
St. Jude Medical Signs Equity Investment and Option to Purchase Agreement with Spinal Modulation Agreement provides St. Jude Medical immediate international distribution rights for the Axium ...
Robert B. Ford is an American businessman and the thirteenth chief executive officer at Abbott Laboratories, a publicly-traded medical devices and health care company based in Abbott Park, Illinois. [1] He received a bachelor's degree from Boston College and an MBA from Haas School of Business. [2]
Another piece of bad news has come out for St. Jude Medical (NYS: STJ) regarding an FDA report on defibrillator lead Durata, bringing shares down 12%. In this video, Motley Fool health-care ...